AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 82
- Registration Number
- NCT02406261
- Locations
- 🇺🇸
Covance Inc, Dallas, Texas, United States
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Terminated
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Other: Patient Reported Outcome (PRO)
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT02405247
- Locations
- 🇰🇷
Research Site, Ulsan, Ulsan Gwangyeogsi, Korea, Republic of
AZD2014 and Weekly Paclitaxel in Squamous NSCLC
Phase 2
Terminated
- Conditions
- Squamous Non Small Cell Lung Cancer
- Interventions
- Drug: Open-label AZD2014
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT02403895
- Locations
- 🇪🇸
Research Site, Girona, Spain
Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet
Phase 1
Completed
- Conditions
- BioavailabilityHealthy Subjects
- Interventions
- Drug: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT02400333
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT02398747
- Locations
- 🇯🇵
Research Site, Kashiwa, Japan
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Phase 3
Withdrawn
- Conditions
- Platinum Sensitive Relapsed Ovarian Cancer
- Interventions
- Drug: PLACEBO
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02392676
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT02388295
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT02375724
- Locations
- 🇬🇧
Research Site, Sidcup, United Kingdom
A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02372344
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Exocrine Pancreatic Insufficiency
- Interventions
- Drug: Epanova® (omega-3 carboxylic acids)Drug: Omacor® (omega-3-acid ethyl esters)
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 490
- Registration Number
- NCT02370537
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden